Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma

被引:0
作者
Li, Sophie [1 ,2 ]
Zheng, Guibin [1 ]
Xu, Li [1 ]
Goswami, Maitrayee [1 ]
Zafereo, Mark E. [1 ]
Sherman, Steven I. [3 ]
Li, Guojun [1 ]
Sturgis, Erich M. [4 ]
Wang, Jennifer R. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] Baylor Coll Med, Sch Med, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX USA
[4] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX USA
关键词
BRAF MUTATION; CANCER-RISK; PREVALENCE; VARIANTS; GERMLINE;
D O I
10.1001/jamaoto.2024.3963
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Importance Genome-wide association studies have identified germline variants associated with the development of papillary thyroid carcinoma (PTC) that can be used to construct a polygenic score (PGS). It is important to determine whether patients with higher germline genetic risk, as summarized using PGS, present with more aggressive disease and/or develop worse clinical outcomes. Objective To assess whether germline risk defined by PGS is associated with clinicopathologic features and survival outcomes for patients with PTC. Design, Setting, and Participants This retrospective cohort study included patients with newly diagnosed PTC who presented to The University of Texas MD Anderson Cancer Center for treatment between 1999 and 2014, with a median follow-up of 12 years. Data were analyzed from December 2023 to April 2024. Exposure Germline risk, as defined by PGS. Main Outcomes and Measures Genomic DNA was extracted from buffy coat cells isolated from peripheral blood samples, and genotyping for germline polymorphisms was performed. Germline risk for PTC was estimated with a previously validated PGS calculated from 10 single-nucleotide variations identified through genome-wide association studies. Stage; PTC-specific survival, defined as the time from PTC diagnosis to death caused by PTC; and overall survival, defined as the time from PTC diagnosis to death by any cause, were analyzed. Results A total of 366 patients were included in the study (261 women [71.3%]; mean [SD] age at diagnosis, 44.3 [13.8] years). There was a statistically significant association between higher PGS and multifocality (beta [SE], 0.40 [0.23]; P = .045) and cervical lymph node involvement (N stage) (beta [SE], 0.62 [0.35]; P = .009) at diagnosis. PGS was associated with PTC-specific survival (hazard ratio, 2.66; 95% CI, 1.03-6.85; P = .04), but this association was not independent of age and overall stage. There was not a statistically significant association between PGS and overall survival. Conclusions and Relevance Findings of this cohort study suggest that patients with a higher germline risk of PTC, as estimated by PGS, present with more aggressive clinicopathologic features. These results contribute to the current understanding of inherited risk in PTC and how germline variants could potentially contribute to disease presentation and clinical outcomes.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [31] BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis
    Walts, Ann E.
    Pao, Andy
    Sacks, Wendy
    Bose, Shikha
    HUMAN PATHOLOGY, 2014, 45 (05) : 935 - 941
  • [32] Computed Tomography Features of Papillary Thyroid Carcinomas
    Kim, Dong Wook
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2014, 38 (06) : 936 - 940
  • [33] The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors
    Choi, Sun Yi
    Park, HeonSoo
    Kang, Myung Koo
    Lee, Dong Kun
    Lee, Kang Dae
    Lee, Hyoung Shin
    Kim, Sung Won
    Lee, Eun Nam
    Hong, Jong Chul
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2013, 11
  • [34] RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients
    Khonrak, Thitima
    Watcharadetwittaya, Sasithorn
    Chamgramol, Yaovalux
    Intarawichian, Piyapharom
    Deenonpoe, Raksawan
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [35] Retrospective study of BRAFV600E mutation and CT features of papillary thyroid carcinoma
    Hong, Xiaoquan
    Li, Juxiang
    Duan, Shaoyin
    You, Youkuang
    PEERJ, 2024, 12
  • [36] Detection of Human Papillomavirus in Papillary Thyroid Carcinoma and its Association with Tumor Staging and Pathologic Features
    Dialameh, Pardisa Archin
    Saki, Forough
    Monabbati, Ahmad
    Dehghanian, Amirreza
    Valibeigi, Behnaz
    Soveid, Mahmood
    IRANIAN JOURNAL OF MEDICAL SCIENCES, 2021, 46 (04) : 256 - 262
  • [37] Clinical and Molecular Features of Papillary Thyroid Cancer in Adolescents and Young Adults
    Vriens, Menno R.
    Moses, Willieford
    Weng, Julie
    Peng, Miao
    Griffin, Ann
    Bleyer, Archie
    Pollock, Brad H.
    Indelicato, Daniel J.
    Hwang, Jimmy
    Kebebew, Electron
    CANCER, 2011, 117 (02) : 259 - 267
  • [38] Cytomorphologic and Molecular Features of Hobnail Variant of Papillary Thyroid Carcinoma: Case Series and Literature Review
    Asioli, Sofia
    Maletta, Francesca
    Pagni, Fabio
    Pacchioni, Donatella
    Vanzati, Alice
    Mariani, Sara
    Palestini, Nicola
    Lloyd, Ricardo V.
    Sapino, Anna
    DIAGNOSTIC CYTOPATHOLOGY, 2014, 42 (01) : 78 - 84
  • [39] The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma
    Lin, Zi-Mei
    Yan, Cao-Xin
    Song, Yue
    Hong, Yu-Rong
    Wen, Qing
    Xu, Yong-Yuan
    Pan, Min-Qiang
    Ye, Qin
    Huang, Pin-Tong
    JOURNAL OF THORACIC DISEASE, 2019, 11 (12) : 5071 - 5078
  • [40] Tall-Cell Variant of Papillary Thyroid Carcinoma: A Matched-Pair Analysis of Survival
    Morris, Luc G. T.
    Shaha, Ashok R.
    Tuttle, R. Michael
    Sikora, Andrew G.
    Ganly, Ian
    THYROID, 2010, 20 (02) : 153 - 158